Primary results of the brazilian registry of atherothrombotic disease (NEAT).

There is limited contemporary prospective real-world evidence of patients with chronic arterial disease in Latin America. The Network to control atherothrombosis (NEAT) registry is a national prospective observational study of patients with known coronary (CAD) and/or peripheral arterial disease (PAD) in Brazil. A total of 2,005 patients were enrolled among 25 sites from September 2020 to March 2022. Patient characteristics, medications and laboratorial data were collected. Primary objective was to assess the proportion of patients who, at the initial visit, were in accordance with good medical practices (domains) for reducing cardiovascular risk in atherothrombotic disease. From the total of patients enrolled, 2 were excluded since they did not meet eligibility criteria. Among the 2,003 subjects included in the analysis, 55.6% had isolated CAD, 28.7% exclusive PAD and 15.7% had both diagnoses. Overall mean age was 66.3 (± 10.5) years and 65.7% were male patients. Regarding evidence-based therapies (EBTs), 4% were not using any antithrombotic drug and only 1.5% were using vascular dose of rivaroxaban (2.5 mg bid). Only 0.3% of the patients satisfied all the domains of secondary prevention, including prescription of EBTs and targets of body-mass index, blood pressure, LDL-cholesterol, and adherence of lifestyle recommendations. The main barrier for prescription of EBTs was medical judgement. Our findings highlight that the contemporary practice does not reflect a comprehensive approach for secondary prevention and had very low incorporation of new therapies in Brazil. Large-scale populational interventions addressing these gaps are warranted to improve the use of evidence-based therapies and reduce the burden of atherothrombotic disease.ClinicalTrials.gov NCT04677725.

Rivaroxaban to prevent major clinical outcomes in non-hospitalised patients with COVID-19: the CARE - COALITION VIII randomised clinical trial.

Background: COVID-19 progression is associated with an increased risk of arterial and venous thrombosis. Randomised trials have demonstrated that anticoagulants reduce the risk of thromboembolism in hospitalised patients with COVID-19, but a benefit of routine anticoagulation has not been demonstrated in the outpatient setting. Methods: We conducted a randomised, open-label, controlled, multicentre study, evaluating the use of rivaroxaban in mild or moderate COVID-19 patients. Adults ≥18 years old, with probable or confirmed SARS-CoV-2 infection, presenting within ≤7 days from symptom onset with no clear indication for hospitalization, plus at least 2 risk factors for complication, were randomised 1:1 either to rivaroxaban 10 mg OD for 14 days or to routine care. The primary efficacy endpoint was the composite of venous thromboembolic events, need of mechanical ventilation, acute myocardial infarction, stroke, acute limb ischemia, or death due to COVID-19 during the first 30 days. ClinicalTrials.gov: NCT04757857. Findings: Enrollment was prematurely stopped due to sustained reduction in new COVID-19 cases. From September 29th, 2020, through May 23rd, 2022, 660 patients were randomised (median age 61 [Q1-Q3 47-69], 55.7% women). There was no significant difference between rivaroxaban and control in the primary efficacy endpoint (4.3% [14/327] vs 5.8% [19/330], RR 0.74; 95% CI: 0.38-1.46). There was no major bleeding in the control group and 1 in the rivaroxaban group. Interpretation: On light of these findings no decision can be made about the utility of rivaroxaban to improve outcomes in outpatients with COVID-19. Metanalyses data provide no evidence of a benefit of anticoagulant prophylaxis in outpatients with COVID-19. These findings were the result of an underpowered study, therefore should be interpreted with caution. Funding: COALITION COVID-19 Brazil and Bayer S.A.

Sex- and Age-Related Impact of the COVID-19 Pandemic on Emergency Department Visits for Chest Pain in Curitiba, Brazil.

BACKGROUND: Women have higher mortality from acute coronary syndrome (ACS) compared with men. Women may hesitate to search for emergency care when experiencing chest pain, which delays treatment. OBJECTIVE: Our aim was to evaluate the changes in emergency visits for chest pain according to sex and age during the COVID-19 pandemic period compared with previous years. METHODS: We collected data on chest pain visits (International Classification of Diseases, Tenth Revision, Clinical Modification codes I20 [unstable angina], I21 [myocardial infarction], and R07.1-4 [chest pain]) from all public emergency departments (EDs) in Curitiba, Brazil. We compared the weekly rates of visits per 100,000 habitants on the epidemiologic weeks 11-52 of 2020 (COVID-19 pandemic period) with the average rates of the same weeks of 2018 and 2019 using Poisson regression. RESULTS: From 2018 to 2020, 37,448 individuals presented to the ED for chest pain, of whom 8493 presented during the COVID-19 pandemic period. Compared with previous years, we observed a 23% reduction in chest pain visits (10.1 vs. 13.0 visits per 100,000 habitants/week; p < 0.001), but this reduction was greater in women than in men (30% vs. 15%; p < 0.001). This reduction was associated with age among women (27%, 31%, and 36% for < 50 years, between 50 and 69 years and > 70 years, respectively, p for age-related trend = 0.041), but not among men. CONCLUSIONS: In this population-level study of Curitiba, Brazil, the reduction in ED visits during the COVID-19 pandemic was greater in women than in men, particularly among those > 70 years of age, suggesting that the sex- and age-related disparities in health care delivery for ACS may have worsened during the COVID-19 pandemic.

Ideal Cardiovascular Health and Job Strain: A Cross-Sectional Study from the Amazon Basin.

BACKGROUND: Ideal Cardiovascular (CV) Health is characterized by four ideal lifestyle parameters and absence of cardiovascular risk factors. The prevalence of ideal CV health in the Amazon Basin and the influence of job strain on CV health in this setting are uncertain. OBJECTIVE: To evaluate the prevalence of ideal CV health and its relationship with job strain in a secluded area from a developing country. METHODS: Job strain was evaluated in 478 employees from an university in the Amazon Basin by a questionnaire that classified participants as passive, active, low or high strain, according to the demand-control model. CV health was evaluated using the American Heart Association 7 health factors (diet, physical activity, body mass index (BMI), smoking, hypertension, diabetes and hypercholesterolemia). Participants were classified as having ideal, intermediate or poor CV health. The level of significance was set at p < 0.05. RESULTS: The mean age was 44.3 ± 12 years, 65% were men, and 35% were faculty. No participant fulfilled the criteria for ideal CV health. Intermediate CV health was found in 44 (9%) and poor in 434 (91%) individuals. Considering low strain as a reference group, individuals classified as high strain, active and passive had a non-significant (p > 0.05) increase in the chances of having poor CV health. When adjusting for possible confounders, high job strain was associated with poor BMI (> 30 kg/m2), (OR 2.11, 95%CI 1.06-4.22; p = 0.034) and poor diet (OR 2.31, 95% CI 1.29-4.13; p = 0.005). CONCLUSION: Job strain was not associated with cardiovascular health, but high job strain was related to obesity and poor diet. Given the high prevalence of poor CV health and lack of participants with ideal CV health, policies focusing on health education and lifestyle interventions are paramount to this population.

Ideal Cardiovascular Health and Job Strain: A Cross-Sectional Study from the Amazon Basin / Saúde Cardiovascular Ideal e Estresse no Trabalho: Um Estudo Transversal da Amazônia Brasileira

Abstract Background: Ideal Cardiovascular (CV) Health is characterized by four ideal lifestyle parameters and absence of cardiovascular risk factors. The prevalence of ideal CV health in the Amazon Basin and the influence of job strain on CV health in this setting are uncertain. Objective: To evaluate the prevalence of ideal CV health and its relationship with job strain in a secluded area from a developing country. Methods: Job strain was evaluated in 478 employees from an university in the Amazon Basin by a questionnaire that classified participants as passive, active, low or high strain, according to the demand-control model. CV health was evaluated using the American Heart Association 7 health factors (diet, physical activity, body mass index (BMI), smoking, hypertension, diabetes and hypercholesterolemia). Participants were classified as having ideal, intermediate or poor CV health. The level of significance was set at p < 0.05. Results: The mean age was 44.3 ± 12 years, 65% were men, and 35% were faculty. No participant fulfilled the criteria for ideal CV health. Intermediate CV health was found in 44 (9%) and poor in 434 (91%) individuals. Considering low strain as a reference group, individuals classified as high strain, active and passive had a non-significant (p > 0.05) increase in the chances of having poor CV health. When adjusting for possible confounders, high job strain was associated with poor BMI (> 30 kg/m2), (OR 2.11, 95%CI 1.06-4.22; p = 0.034) and poor diet (OR 2.31, 95% CI 1.29-4.13; p = 0.005). Conclusion: Job strain was not associated with cardiovascular health, but high job strain was related to obesity and poor diet. Given the high prevalence of poor CV health and lack of participants with ideal CV health, policies focusing on health education and lifestyle interventions are paramount to this population.

Resumo Fundamento: Saúde cardiovascular (CV) ideal é caracterizada por quatro parâmetros de estilo de vida ideal e ausência de fatores de risco CV. A prevalência da saúde CV ideal na Bacia Amazônica e sua relação com estresse no trabalho é desconhecida. Objetivo: Avaliar a prevalência da saúde CV ideal e sua relação com o estresse no trabalho em uma área isolada de um país em desenvolvimento. Métodos: O estresse no trabalho foi avaliado em 478 funcionários de uma universidade na Bacia Amazônica através de um questionário validado que classificou os participantes como passivos, ativos, baixa tensão ou alta tensão no trabalho, de acordo com o modelo de demanda e controle. A saúde CV foi avaliada usando os 7 parâmetros usados pela American Heart Association (dieta, atividade física, IMC, tabagismo, hipertensão, diabetes e hipercolesterolemia). Os participantes foram classificados em saúde CV ideal, intermediária ou ruim. O nível de significância adotado foi de 5% (p < 0,05). Resultados: A idade média foi de 44,3 ± 12 anos, 65% eram homens e 35% eram professores. Nenhum participante preencheu os critérios de saúde CV ideal. A saúde CV intermediária foi encontrada em 44 (9%) e ruim em 434 (91%) dos entrevistados. Considerando a baixa tensão como grupo de referência, indivíduos classificados como de alta tensão, ativos e passivos tiveram um aumento não significativo (p > 0,05) nas chances de ter saúde CV ruim. Ao ajustar para possíveis fatores de confusão, a alta tensão no trabalho foi associada à obesidade (IMC > 30 kg/m2): OR 2,11 (IC 95% 1,06-4,22; p = 0,034) e dieta inadequada: OR 2,31 (IC 95%: 1,29-4,13 p = 0,005). Conclusão: Não houve associação entre saúde CV e estresse no trabalho, mas a obesidade e a má alimentação foram relacionadas à alta tensão. Dada a alta prevalência de saúde CV ruim e ausência de participantes com saúde CV ideal, as políticas voltadas para a educação em saúde e as intervenções de estilo de vida são primordiais para essa população.

Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda

INTRODUÇÃO: A organização de uma diretriz clínica é tarefa complexa, que necessariamente deve envolver planejamento prévio, coordenação apropriada, revisão aprofundada da literatura científica, com envolvimento de múltiplos profissionais da área da saúde com notório reconhecimento. A elaboração de uma diretriz clínica de insuficiência cardíaca é ainda mais difícil, por conta da complexidade da síndrome, da amplitude das evidências científicas que permeiam o tópico e do grande impacto que as recomendações propostas têm sobre os pacientes, a comunidade médica e a sociedade como um todo. No presente documento, o Departamento de Insuficiência Cardíaca (DEIC) da Sociedade Brasileira de Cardiologia (SBC) apresenta uma revisão e uma atualização detalhadas de sua Diretriz de Insuficiência Cardíaca Crônica. Os trabalhos se iniciaram em setembro de 2017, com a definição da Comissão Coordenadora, que estabeleceu prioridades, dividiu grupos de trabalho e definiu o cronograma das atividades. Os grupos de trabalho, compostos por três a cinco participantes, deram início a intensas discussões virtuais, que culminaram com a redação de tabelas preliminares, sendo posteriormente amplamente divulgadas e revisadas pelos 34 participantes da diretriz. As discussões finais foram realizadas em reunião presencial em março de 2018, com a participação de todos os colaboradores, nas quais as principais recomendações foram votadas individualmente. As decisões quanto à classe das recomendações foram definidas por maioria plena (concordância de mais de 75% dos participantes). As recomendações terapêuticas propostas no presente documento se embasam nas evidências científicas mais atuais, considerando não apenas aspectos de eficácia clínica demonstrados em grandes ensaios clínicos, mas também contextualizando seus achados para o cenário de saúde brasileiro e incorporando aspectos econômicos definidos em estudos de custo-efetividade. Buscamos sumarizar as principais recomendações em fluxogramas e algoritmos de fácil entendimento e grande aplicabilidade clínica, propondo abordagens para o diagnóstico e o tratamento da síndrome em formato moderno, atualizado e didático. Na última seção da diretriz, o que não podemos deixar de fazer e o que não devemos fazer no diagnóstico, prevenção e tratamento da síndrome foram sumarizados em apenas três tabelas. Em especial, destacamos seis intervenções que foram consideradas de alta prioridade, por apresentarem relações de custo-efetividade altamente favoráveis. Sobretudo, esperamos que a publicação deste documento possa auxiliar na redução das elevadas taxas de mortalidade que ainda estão associadas com a insuficiência cardíaca no Brasil, além de minimizar o cruel impacto que a síndrome causa na qualidade de vida de nossos pacientes. Acreditamos que esta diretriz apresenta, de forma hierarquizada, a linha mestra que deve nortear a prática clínica em diferentes níveis de atenção à saúde, permitindo reconhecimento precoce de pacientes em risco, diagnóstico apropriado e implementação de tratamento de forma escalonada, eficaz e coerente com nossa realidade.

Second generation drug-eluting stents versus bare-metal stents for percutaneous coronary intervention of the proximal left anterior descending artery: An analysis of the BASKET-PROVE I and II trials.

OBJECTIVES: To compare mid-term outcomes between patients undergoing proximal left anterior descending artery (LAD) percutaneous coronary intervention (PCI) with second generation drug-eluting stent (DES) or bare-metal stent (BMS). BACKGROUND: PCI with BMS and first-generation DES have shown to be safe options for the treatment of proximal LAD stenosis, however associated with considerable reintervention rates. Overall, second-generation DES has proven to be superior to BMS and first-generation DES, nevertheless, its effect for proximal LAD PCI has not previously been reported. METHODS: We analyzed 2-year outcomes of 1,100 patients from the BASKET-PROVE I and II trials, referred for proximal LAD PCI with second generation DES (n = 680) or BMS (n = 420). RESULTS: The cumulative 2-year incidence of major adverse cardiac events (MACE, composite of cardiac death, myocardial infarction (MI) and target vessel revascularization (TVR)) was lower in second generation DES than in BMS treated patients (7.3% vs. 12.3%; HR 0.57, 95% CI 0.39/0.85), mainly driven by a reduced rate of TVR (3.7% vs. 10.0%; HR 0.35, CI 0.21/0.58). No difference was found in cardiac death (1.9% vs. 1.9%; HR 1.01, CI 0.42/2.44) and MI (4.4% vs. 4.7%; HR 0.93, CI 0.53/1.64). The benefit of DES use seemed to be more prominent in female patients with a reduction in MACE (P for interaction = 0.025). CONCLUSIONS: In patients with proximal LAD stenosis, treatment with second-generation DES was associated with reduced 2-year rates of adverse cardiac events and TVR compared to BMS, with reintervention rates similar to those earlier reported from bypass surgery.